Aromatase is the major enzyme metabolizing buprenorphine in human placenta

Sujal V. Deshmukh, Tatiana Nanovskaya, Mahmoud Ahmed

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Buprenorphine (BUP) is a partial opiate agonist used for treatment of the adult and the pregnant addicted to this class of narcotics. The kinetic parameters for transplacental transfer and the metabolism of BUP during its perfusion in a placental lobule were the subject of an earlier report from our laboratory. The aim of this investigation is to identify and characterize the enzyme catalyzing the metabolism of BUP in term human placenta. Norbuprenorphine (norBUP) is the only metabolite formed as determined by high performance liquid chromatography and mass spectrometry. The activity of the enzyme responsible for BUP metabolism is highest in the microsomal fraction and lowest in the cytosolic, with the mitochondrial in between. Compounds with selective affinity to the enzyme aromatase (CYP 19), namely 4-hydroxyandrostenedione and aminoglutethimide, caused >70% inhibition of norBUP formation. Monoclonal antibodies raised against CYP 19 were the most potent inhibitors of BUP dealkylation. A comparison between the data obtained from the saturation isotherm for BUP dealkylation by placental microsomes and a commercially available system of cDNA-expressed CYP 19 indicated similar kinetic parameters, with apparent Km values of 12 ± 4.0 and 14 ± 8.0 μM, respectively. Therefore, aromatase is the major enzyme catalyzing the biotransformation of BUP to norBUP in term human placentas obtained from healthy pregnancies. The minor involvement of other cytochrome P450 isoforms or enzyme(s) in the metabolism of BUP in placental tissue cannot be ruled out.

Original languageEnglish (US)
Pages (from-to)1099-1105
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume306
Issue number3
DOIs
StatePublished - Sep 1 2003

Fingerprint

Buprenorphine
Aromatase
Placenta
Enzymes
Dealkylation
Opiate Alkaloids
Aminoglutethimide
Narcotics
Biotransformation
Microsomes
Cytochrome P-450 Enzyme System
Mass Spectrometry
Protein Isoforms
Complementary DNA
Perfusion
High Pressure Liquid Chromatography
Monoclonal Antibodies
Pregnancy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Aromatase is the major enzyme metabolizing buprenorphine in human placenta. / Deshmukh, Sujal V.; Nanovskaya, Tatiana; Ahmed, Mahmoud.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 306, No. 3, 01.09.2003, p. 1099-1105.

Research output: Contribution to journalArticle

@article{b7d90fce62ff40fab0a4b87e43bfb407,
title = "Aromatase is the major enzyme metabolizing buprenorphine in human placenta",
abstract = "Buprenorphine (BUP) is a partial opiate agonist used for treatment of the adult and the pregnant addicted to this class of narcotics. The kinetic parameters for transplacental transfer and the metabolism of BUP during its perfusion in a placental lobule were the subject of an earlier report from our laboratory. The aim of this investigation is to identify and characterize the enzyme catalyzing the metabolism of BUP in term human placenta. Norbuprenorphine (norBUP) is the only metabolite formed as determined by high performance liquid chromatography and mass spectrometry. The activity of the enzyme responsible for BUP metabolism is highest in the microsomal fraction and lowest in the cytosolic, with the mitochondrial in between. Compounds with selective affinity to the enzyme aromatase (CYP 19), namely 4-hydroxyandrostenedione and aminoglutethimide, caused >70{\%} inhibition of norBUP formation. Monoclonal antibodies raised against CYP 19 were the most potent inhibitors of BUP dealkylation. A comparison between the data obtained from the saturation isotherm for BUP dealkylation by placental microsomes and a commercially available system of cDNA-expressed CYP 19 indicated similar kinetic parameters, with apparent Km values of 12 ± 4.0 and 14 ± 8.0 μM, respectively. Therefore, aromatase is the major enzyme catalyzing the biotransformation of BUP to norBUP in term human placentas obtained from healthy pregnancies. The minor involvement of other cytochrome P450 isoforms or enzyme(s) in the metabolism of BUP in placental tissue cannot be ruled out.",
author = "Deshmukh, {Sujal V.} and Tatiana Nanovskaya and Mahmoud Ahmed",
year = "2003",
month = "9",
day = "1",
doi = "10.1124/jpet.103.053199",
language = "English (US)",
volume = "306",
pages = "1099--1105",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Aromatase is the major enzyme metabolizing buprenorphine in human placenta

AU - Deshmukh, Sujal V.

AU - Nanovskaya, Tatiana

AU - Ahmed, Mahmoud

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Buprenorphine (BUP) is a partial opiate agonist used for treatment of the adult and the pregnant addicted to this class of narcotics. The kinetic parameters for transplacental transfer and the metabolism of BUP during its perfusion in a placental lobule were the subject of an earlier report from our laboratory. The aim of this investigation is to identify and characterize the enzyme catalyzing the metabolism of BUP in term human placenta. Norbuprenorphine (norBUP) is the only metabolite formed as determined by high performance liquid chromatography and mass spectrometry. The activity of the enzyme responsible for BUP metabolism is highest in the microsomal fraction and lowest in the cytosolic, with the mitochondrial in between. Compounds with selective affinity to the enzyme aromatase (CYP 19), namely 4-hydroxyandrostenedione and aminoglutethimide, caused >70% inhibition of norBUP formation. Monoclonal antibodies raised against CYP 19 were the most potent inhibitors of BUP dealkylation. A comparison between the data obtained from the saturation isotherm for BUP dealkylation by placental microsomes and a commercially available system of cDNA-expressed CYP 19 indicated similar kinetic parameters, with apparent Km values of 12 ± 4.0 and 14 ± 8.0 μM, respectively. Therefore, aromatase is the major enzyme catalyzing the biotransformation of BUP to norBUP in term human placentas obtained from healthy pregnancies. The minor involvement of other cytochrome P450 isoforms or enzyme(s) in the metabolism of BUP in placental tissue cannot be ruled out.

AB - Buprenorphine (BUP) is a partial opiate agonist used for treatment of the adult and the pregnant addicted to this class of narcotics. The kinetic parameters for transplacental transfer and the metabolism of BUP during its perfusion in a placental lobule were the subject of an earlier report from our laboratory. The aim of this investigation is to identify and characterize the enzyme catalyzing the metabolism of BUP in term human placenta. Norbuprenorphine (norBUP) is the only metabolite formed as determined by high performance liquid chromatography and mass spectrometry. The activity of the enzyme responsible for BUP metabolism is highest in the microsomal fraction and lowest in the cytosolic, with the mitochondrial in between. Compounds with selective affinity to the enzyme aromatase (CYP 19), namely 4-hydroxyandrostenedione and aminoglutethimide, caused >70% inhibition of norBUP formation. Monoclonal antibodies raised against CYP 19 were the most potent inhibitors of BUP dealkylation. A comparison between the data obtained from the saturation isotherm for BUP dealkylation by placental microsomes and a commercially available system of cDNA-expressed CYP 19 indicated similar kinetic parameters, with apparent Km values of 12 ± 4.0 and 14 ± 8.0 μM, respectively. Therefore, aromatase is the major enzyme catalyzing the biotransformation of BUP to norBUP in term human placentas obtained from healthy pregnancies. The minor involvement of other cytochrome P450 isoforms or enzyme(s) in the metabolism of BUP in placental tissue cannot be ruled out.

UR - http://www.scopus.com/inward/record.url?scp=0042934006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042934006&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.053199

DO - 10.1124/jpet.103.053199

M3 - Article

VL - 306

SP - 1099

EP - 1105

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -